Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx Group (MDXG) Gross Margin: 2011-2025

Historic Gross Margin for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to 83.54%.

  • Mimedx Group's Gross Margin rose 177.00% to 83.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.99%, marking a year-over-year decrease of 138.00%. This contributed to the annual value of 82.78% for FY2024, which is 22.00% down from last year.
  • As of Q3 2025, Mimedx Group's Gross Margin stood at 83.54%, which was up 3.07% from 81.05% recorded in Q2 2025.
  • Mimedx Group's 5-year Gross Margin high stood at 86.03% for Q4 2021, and its period low was 80.68% during Q4 2022.
  • Over the past 3 years, Mimedx Group's median Gross Margin value was 82.67% (recorded in 2023), while the average stood at 82.63%.
  • In the last 5 years, Mimedx Group's Gross Margin tumbled by 535bps in 2022 and then surged by 338bps in 2023.
  • Quarterly analysis of 5 years shows Mimedx Group's Gross Margin stood at 86.03% in 2021, then crashed by 535bps to 80.68% in 2022, then surged by 338bps to 84.06% in 2023, then slumped by 226bps to 81.80% in 2024, then soared by 177bps to 83.54% in 2025.
  • Its Gross Margin stands at 83.54% for Q3 2025, versus 81.05% for Q2 2025 and 81.23% for Q1 2025.